Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

How Many COVID Vaccine Doses Will Pfizer and Moderna Distribute by Year-End?

By Keith Speights - Dec 13, 2020 at 4:05PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Hint: It's a big number -- but not nearly big enough.

Good news could be right around the corner. Pfizer ( PFE 1.77% ) and Moderna ( MRNA -11.87% ) hope to soon win FDA emergency use authorizations (EUA) for their respective COVID-19 vaccines. Assuming all goes well, the drugmakers could ship their vaccines this month.

In this Motley Fool Live video recorded on Dec. 3, 2020, Healthcare and Cannabis Bureau Chief Corinne Cardina and Fool.com writer Keith Speights discuss how many doses Pfizer and Moderna will realistically be able to make available to Americans by the end of the year.

Corinne Cardina: In terms of dosing, how many doses have Pfizer and Moderna said that they will be able to produce and what's the timeline there?

Keith Speights: Pfizer has stated that they would be able to produce up to 50 million doses by the end of the year. Moderna has said they will be able to produce around 20 million doses.

But the thing to keep in mind there is Pfizer particularly included the word "globally" in their statements. So 50 million doses globally doesn't mean all of those go to the US.

I think the best estimate is what the CDC is saying, they have reported that they're expecting around 40 million doses available for Americans by the end of the year between those two vaccines. Then after that, receiving 5-10 million new doses per week.

I would go with that 40 million dose level by the end of the year. That's probably more accurate than totaling the 50 and 20 million doses that Pfizer and Moderna have said.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$54.68 (1.77%) $0.95
Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$310.61 (-11.87%) $-41.82

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
656%
 
S&P 500 Returns
144%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/02/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.